Tomahawk, WI 07/07/2014 (Basicsmedia) – Pfizer Inc. (NYSE:PFE) is a drug manufacturing company that is treading higher up, on a rising spree, but the trend might just be hit lately, after the recent expiry of the company’s patent on an important drug called Viagra, that treats erectile dysfunction, in the provinces of China.

Viagra’s Patent Rights Expiry

Yangtse Evening Post, based in Nanjing stated that this has opened up the Chinese market, making it deemed fit for circulation of generic drugs.  The US based Pfizer Inc. (NYSE:PFE) lost its rights pertaining to patent protection in China on May 12. The CFDA – China Food and Drug Administration had come up with these statistical data. It was also revealed that over 12 drug-makers have applied for a myriad versions of Viagra to the CFDA; the processes were initiated around a couple of years ago!

The Viagra Market

China has a wide spectrum of issues pertaining to erectile dysfunction. Estimates suggest that China has a humongous market for erectile dysfunction drugs, estimated at around $9.67 billion, each year. Apart from Viagra, two other forms of erectile dysfunction drugs widely available in the market are Levitra and Cialis.

However, Viagra is considered the most popular and widely used drug amongst Chinese consumers. Pfizer Inc. (NYSE:PFE)’s Viagra accounted for 58.8% of the net sales of drugs that treat erectile dysfunction problems, across 27 major Chinese cities in FY 2013.

No Chances Of Low Cost Viagra!

PFE China has corroborated no evidence of launching a holistically reckoned low cost Viagra drug, to compete with the generic drugmaker competitors, post-expiration of patent. The Communication Director of PFE China, Xi Qing commented that any research based erectile dysfunction drug maker would pass through the ordeal of patent expiry.

Xi Qing’s statement reverberated immense conviction in Pfizer Inc. (NYSE:PFE)’s Viagra, when he said that such an expiry doesn’t really mean the end of any product. This clearly showed the confidence Xi Qing showed for his drug and the lack of the same on its strong contenders.

It must be remembered that PFE was forced to launch a Viagra called White Diamond – a low cost variance of Viagra drugs across Europe, in order to compete with the enumerable generic drug-makers.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.